PlexBio Co., Ltd. (TPEX:6572)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
8.08
-0.23 (-2.77%)
At close: Feb 11, 2026
Market Cap837.49M -30.9%
Revenue (ttm)153.06M +47.7%
Net Income-64.51M
EPS-0.62
Shares Out103.65M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume24,514
Average Volume261,954
Open8.32
Previous Close8.31
Day's Range7.96 - 8.32
52-Week Range7.20 - 12.70
Beta0.19
RSI45.75
Earnings DateApr 27, 2026

About PlexBio

PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It offers workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for πCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular testing; and πCode coupling buffer sets. PlexBio Co., Ltd. was founded in 2009 and is based in Taipei, Taiwan. [Read more]

Sector Healthcare
Founded 2009
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6572
Full Company Profile

Financial Performance

In 2024, PlexBio's revenue was 128.06 million, a decrease of -23.40% compared to the previous year's 167.18 million. Losses were -61.63 million, 5.30% more than in 2023.

Financial Statements